P

Peter MacCallum Cancer Centre | Department of Clinical Hematology

Research site
(Unclaimed)
Location
305 Grattan Street, Melbourne, Victoria, Australia
Site insights

Top conditions

Cancer (43 trials)

Prostatic Cancer (37 trials)

Lymphoma (27 trials)

Breast Cancer (25 trials)

Non-Small-Cell Lung Carcinoma (21 trials)

Top treatments

Pembrolizumab
Atezolizumab
Tislelizumab
Palbociclib
Lenalidomide
Abemaciclib
Cisplatin
Encorafenib
LY2835219
Platinum

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

138 of 307
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

This is a Phase I, FIH, open-label, multicenter, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin...

Enrolling
Solid Tumor
Biological: CLDN6 CAR-T
Biological: CLDN6 uRNA-LPX/CLDN6 modRNA-LPX

The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (...

Enrolling
Neuroendocrine Tumors
Drug: 64Cu-SARTATE

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK...

Enrolling
Non-Hodgkin's Lymphoma
Drug: Glofitamab
Drug: Obinutuzumab

To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer thera...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Drug: Pembrolizumab
Drug: ERAS-601

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Drug: BGB-16673

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common res...

Enrolling
Child
Neoplasms
Drug: Irinotecan
Drug: Ramucirumab

This is an open label, multi-centre, phase Ib/II, parallel arm study evaluating the safety and tolerability of glofitamab in addition to backbone che...

Active, not recruiting
High-grade B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Drug: Rituximab
Drug: Polatuzumab vedotin

The main purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relap...

Active, not recruiting
T-cell Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Biological: WU-CART-007

The three tumour streams that will be studied in this protocol are: (i) upper GI malignancies (comprising intra-hepatic/extra-hepatic cholangiocarcin...

Active, not recruiting
Malignant Female Reproductive System Neoplasm
Neuroendocrine Tumours
Drug: Ipilimumab
Drug: Nivolumab

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituxima...

Enrolling
Diffuse Large B-cell Lymphoma
Drug: Oxaliplatin
Drug: Rituxumab

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant...

Active, not recruiting
Soft Tissue Sarcoma of the Extremity
Drug: Pembrolizumab

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malig...

Active, not recruiting
Adult B Cell ALL
B-cell Lymphoma
Biological: CTX110

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory mul...

Active, not recruiting
Multiple Myeloma
Biological: CTX120

The purpose of this study is to compare the efficacy of JNJ-68284528 (ciltacabtagene autoleucel [cilta-cel]) with standard therapy, either Pomalidomi...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemoth...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: Sotorasib
Drug: Pembrolizumab

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. Cohort 1 will focus on participants wit...

Enrolling
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Drug: Palbociclib
Drug: Inavolisib

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combina...

Enrolling
Metastatic Colorectal Cancer
Drug: Inavolisib
Drug: Cetuximab

This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharm...

Enrolling
Advanced Solid Tumors
Drug: Tislelizumab
Drug: BGB-30813

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after...

Active, not recruiting
Breast Neoplasms
Drug: Placebo
Drug: Abemaciclib

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants wi...

Active, not recruiting
Prostate Cancer
Drug: Abiraterone Acetate
Drug: Placebo

Trial sponsors

P

Peter MacCallum Cancer Centre, Australia (55 trials)

Pfizer logo

Pfizer (20 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems